206361-99-1 | Darunavir

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$25.00	$18.00
250mg	98%	in stock	$40.00	$28.00
1g	98%	in stock	$102.00	$71.00
5g	98%	in stock	$331.00	$232.00
25g	98%	in stock	$1,153.00	$807.00

Description

• Catalog Number: AD61200
• Chemical Name: Darunavir
• CAS Number: 206361-99-1
• Molecular Formula: C27H37N3O7S
• Molecular Weight: 547.6636
• MDL Number: MFCD09260006
• SMILES: CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)C

Computed Properties

• Complexity: 853
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 38
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 12
• XLogP3: 2.9

Literature

• Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.

  ChemMedChem 20171207

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

  Journal of virology 20140301

• GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

  Antimicrobial agents and chemotherapy 20131201

• P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.

  Antimicrobial agents and chemotherapy 20131001

• Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

  Chemistry & biology 20130919

• Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20130912

• GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20130501

• In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.

  The Journal of antimicrobial chemotherapy 20130101

• Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.

  Bioorganic & medicinal chemistry letters 20130101

• Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.

  Proteins 20121201

• Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

  Journal of clinical pharmacology 20121101

• Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

  Antimicrobial agents and chemotherapy 20121101

• Treatment of HIV infection with once-daily regimens.

  Expert opinion on pharmacotherapy 20121101

• Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

  AIDS research and human retroviruses 20121001

• Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20121001

• Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20121001

• Antiretroviral neurotoxicity.

  Journal of neurovirology 20121001

• Liquid chromatographic separation and thermodynamic investigation of stereoisomers of darunavir on Chiralpak AD-H column.

  Journal of separation science 20121001

• Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

  AIDS (London, England) 20120910

• Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

  AIDS research and human retroviruses 20120901

• Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.

  HIV medicine 20120901

• High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

  The Journal of antimicrobial chemotherapy 20120901

• Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.

  Fundamental & clinical pharmacology 20120801

• Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120801

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

  HIV medicine 20120801

• Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Liquid chromatographic separation of darunavir enantiomers on coated and immobilized amylose tris(3, 5-dimethylphenylcarbamate) chiral stationary phases.

  Chirality 20120801

• Enamino-oxindole HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20120801

• Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.

  AIDS (London, England) 20120731

• Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20120726

• Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

  JAMA 20120725

• Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.

  The Journal of antimicrobial chemotherapy 20120701

• Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.

  Antimicrobial agents and chemotherapy 20120701

• Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?

  Medicinal research reviews 20120701

• Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans.

  Canadian journal of microbiology 20120701

• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

  The Lancet. Infectious diseases 20120701

• Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

  International journal of STD & AIDS 20120701

• Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.

  Journal of medicinal chemistry 20120628

• Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.

  Journal of chemical information and modeling 20120625

• Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.

  Journal of clinical pharmacology 20120601

• Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.

  AIDS research and human retroviruses 20120601

• Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

  Infection 20120601

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• [Characteristics of human immunodeficiency virus-1 infected children receiving highly active antiretroviral therapy: a cross-sectional study].

  Anales de pediatria (Barcelona, Spain : 2003) 20120601

• Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

  The Journal of antimicrobial chemotherapy 20120601

• Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

  The Journal of antimicrobial chemotherapy 20120601

• High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.

  Therapeutic drug monitoring 20120601

• Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.

  Expert opinion on pharmacotherapy 20120601

• A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

  PLoS pathogens 20120601

• Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

  Journal of medicinal chemistry 20120412

• HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

  Biochemistry 20120403

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

  The Journal of antimicrobial chemotherapy 20120401

• Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401

• Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.

  Journal of natural products 20120323

• Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

  Bioorganic & medicinal chemistry letters 20120315

• Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.

  AIDS (London, England) 20120313

• Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.

  HIV medicine 20120301

• Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.

  The Journal of antimicrobial chemotherapy 20120301

• Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

  The Journal of antimicrobial chemotherapy 20120301

• Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

  Protein science : a publication of the Protein Society 20120301

• Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.

  The journal of physical chemistry. B 20120301

• Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.

  Applied health economics and health policy 20120301

• Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

  Current HIV research 20120301

• Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.

  International journal of STD & AIDS 20120301

• Rational approaches to improving selectivity in drug design.

  Journal of medicinal chemistry 20120223

• Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.

  The journal of physical chemistry. B 20120216

• Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease.

  Biochemistry 20120207

• Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

  Pharmacological research 20120201

• Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20120201

• Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120201

• The good, the bad and the twisted: a survey of ligand geometry in protein crystal structures.

  Journal of computer-aided molecular design 20120201

• Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.

  AIDS (London, England) 20120128

• [Safety and effectiveness of salvage therapy in HIV patients].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding.

  Methods in molecular biology (Clifton, N.J.) 20120101

• First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.

  The American journal of tropical medicine and hygiene 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• Special aspects of the treatment of HIV-2-infected patients.

  Intervirology 20120101

• Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

  Antiviral therapy 20120101

• The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

  Antiviral therapy 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex.

  PloS one 20120101

• Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

  Retrovirology 20120101

• HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

  PloS one 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

  HIV clinical trials 20120101

• Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics.

  PloS one 20120101

• Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

  AIDS research and treatment 20120101

• New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

  AIDS research and treatment 20120101

• Impact of hepatitis C co-infection on response to antiretroviral treatment.

  AIDS reviews 20120101

• Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.

  PloS one 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.

  Mediterranean journal of hematology and infectious diseases 20120101

• Darunavir: a critical review of its properties, use and drug interactions.

  Pharmacology 20120101

• Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

  Journal of the National Medical Association 20120101

• Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20111215

• Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.

  Alcoholism, clinical and experimental research 20111201

• TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

  Antimicrobial agents and chemotherapy 20111201

• Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.

  Drugs in R&D 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

  AIDS (London, England) 20111113

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101

• Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.

  International journal of STD & AIDS 20111101

• Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

  The Journal of infectious diseases 20111015

• Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.

  Paediatric drugs 20111001

• The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.

  Biochemical and biophysical research communications 20110909

• A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

  AIDS care 20110901

• Protease inhibitor monotherapy and the CNS: peace of mind?

  The Journal of antimicrobial chemotherapy 20110901

• Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

  The Journal of antimicrobial chemotherapy 20110901

• [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].

  Medecine et maladies infectieuses 20110901

• Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

  Journal of medicinal chemistry 20110825

• Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.

  AIDS (London, England) 20110824

• Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110815

• 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

  The Journal of antimicrobial chemotherapy 20110801

• Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.

  Journal of biomolecular structure & dynamics 20110801

• Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

  AIDS research and human retroviruses 20110701

• Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.

  AIDS research and human retroviruses 20110701

• Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

  The Journal of antimicrobial chemotherapy 20110701

• Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.

  The new microbiologica 20110701

• Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.

  AIDS (London, England) 20110619

• Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.

  Bioorganic & medicinal chemistry letters 20110615

• Tetherin and its viral antagonists.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110601

• Management of HIV infection in treatment-naive patients: a review of the most current recommendations.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110601

• Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.

  AIDS patient care and STDs 20110601

• Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.

  Acta crystallographica. Section D, Biological crystallography 20110601

• Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.

  Current HIV research 20110601

• Darunavir: an effective protease inhibitor for HIV-infected patients.

  Expert review of anti-infective therapy 20110601

• The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

  Biochemistry 20110531

• Risk of triple-class virological failure in children with HIV: a retrospective cohort study.

  Lancet (London, England) 20110507

• Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.

  HIV medicine 20110501

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

  Bioanalysis 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.

  Journal of acquired immune deficiency syndromes (1999) 20110501

• Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

  AIDS (London, England) 20110424

• Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

  AIDS (London, England) 20110424

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

  Antimicrobial agents and chemotherapy 20110401

• Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

  Clinical pharmacokinetics 20110401

• Clinical applications of drug desensitization in the Asia-Pacific region.

  Asia Pacific allergy 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene.

  HIV medicine 20110301

• Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

  Pharmacological research 20110301

• Levels of adherence required for virologic suppression among newer antiretroviral medications.

  The Annals of pharmacotherapy 20110301

• Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.

  Journal of clinical pharmacology 20110201

• The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

  Journal of clinical pharmacology 20110201

• Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110201

• Emerging antiretroviral drug interactions.

  The Journal of antimicrobial chemotherapy 20110201

• Protease inhibitor monotherapy.

  Current opinion in infectious diseases 20110201

• Pharmacoeconomics of darunavir.

  Expert review of pharmacoeconomics & outcomes research 20110201

• Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

  Journal of medicinal chemistry 20110127

• Darunavir/ritonavir monotherapy in clinical practice.

  AIDS (London, England) 20110102

• Recent advances in antiretroviral drugs.

  Expert opinion on pharmacotherapy 20110101

• 800 mg Darunavir tablets prepared by hot melt extrusion.

  Pharmaceutical development and technology 20110101

• Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.

  The Journal of antimicrobial chemotherapy 20110101

• Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions.

  Journal of medicinal food 20110101

• Indications for the use of next-generation antiretroviral drugs in current clinical practice.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Long-term safety from the raltegravir clinical development program.

  Current HIV research 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Human Herpesvirus-8 Infection Associated with Kaposi Sarcoma, Multicentric Castleman's Disease, and Plasmablastic Microlymphoma in a Man with AIDS: A Case Report with Review of Pathophysiologic Processes.

  Pathology research international 20110101

• Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

  Journal of translational medicine 20110101

• Human immunodeficiency virus type 2 in two Saudi families.

  Annals of Saudi medicine 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

  Antiviral therapy 20110101

• Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

  Antiviral therapy 20110101

• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  AIDS research and therapy 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV.

  AIDS research and therapy 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease.

  Retrovirology 20110101

• Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series.

  Radiation oncology (London, England) 20110101

• Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

  PloS one 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.

  Virology journal 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

  The open medicinal chemistry journal 20110101

• A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

  PloS one 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

  HIV clinical trials 20110101

• Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

  Antiviral therapy 20110101

• Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

  PloS one 20110101

• Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

  PloS one 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Recent developments of peptidomimetic HIV-1 protease inhibitors.

  Current medicinal chemistry 20110101

• Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.

  Antiviral therapy 20110101

• Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients.

  AIDS reviews 20110101

• Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions.

  Retrovirology 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

  PloS one 20110101

• Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.

  BMC infectious diseases 20110101

• Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.

  Doklady. Biochemistry and biophysics 20110101

• Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

  PloS one 20110101

• The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.

  PloS one 20110101

• Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease in a Patient with HIV Infection: Dual Clinical Benefit.

  Case reports in neurology 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

  ClinicoEconomics and outcomes research : CEOR 20110101

• A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

  BMC bioinformatics 20110101

• Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.

  HIV clinical trials 20110101

• Nanomedicine as an emerging approach against intracellular pathogens.

  International journal of nanomedicine 20110101

• A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

  Patient preference and adherence 20110101

• Synthesis and Inhibiting Activity of Some 4-Hydroxycoumarin Derivatives on HIV-1 Protease.

  ISRN pharmaceutics 20110101

• Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

  Acta naturae 20110101

• Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.

  AIDS research and human retroviruses 20101201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101201

• HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.

  The Indian journal of medical research 20101201

• A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).

  Drugs of today (Barcelona, Spain : 1998) 20101201

• Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

  AIDS (London, England) 20101113

• Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.

  Journal of medicinal chemistry 20101111

• Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

  ChemMedChem 20101108

• Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.

  HIV medicine 20101101

• Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance.

  Protein science : a publication of the Protein Society 20101101

• Impact of drug transporters on cellular resistance towards saquinavir and darunavir.

  The Journal of antimicrobial chemotherapy 20101101

• Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

  AIDS research and human retroviruses 20101101

• Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

  Clinical pharmacology and therapeutics 20101101

• Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.

  Advances in therapy 20101101

• Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.

  The Annals of pharmacotherapy 20101101

• A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).

  AIDS research and human retroviruses 20101101

• HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.

  Biopharmaceutics & drug disposition 20101101

• Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.

  International journal of STD & AIDS 20101101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101101

• Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

  Viruses 20101101

• Molecular Basis for Drug Resistance in HIV-1 Protease.

  Viruses 20101101

• Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected men.

  AIDS (London, England) 20101023

• Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

  AIDS (London, England) 20101023

• Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

  AIDS (London, England) 20101023

• Co-administration of darunavir and a new pharmacokinetic booster: formulation strategies and evaluation in dogs.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009

• First antiretroviral patent in global drug pool puts pressure on companies to follow suit.

  BMJ (Clinical research ed.) 20101005

• Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

  The Journal of antimicrobial chemotherapy 20101001

• Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

  AIDS (London, England) 20100924

• Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

  Annals of internal medicine 20100921

• Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

  Drugs 20100910

• HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

  Journal of pharmaceutical and biomedical analysis 20100905

• In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20100801

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation.

  AIDS (London, England) 20100731

• A medicinal chemist's guide to molecular interactions.

  Journal of medicinal chemistry 20100722

• Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

  The Journal of antimicrobial chemotherapy 20100701

• Analysis of resistance testing in South Trinidad.

  The West Indian medical journal 20100701

• Role of Gag in HIV Resistance to Protease Inhibitors.

  Viruses 20100701

• Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.

  Journal of pharmaceutical sciences 20100601

• Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.

  Current HIV research 20100601

• Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.

  Expert opinion on pharmacotherapy 20100601

• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

  Biochimica et biophysica acta 20100501

• Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

  Journal of virological methods 20100501

• Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

  Journal of virology 20100501

• Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.

  Clinical pharmacokinetics 20100501

• Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

  British journal of clinical pharmacology 20100501

• Special issue: retroviral enzymes.

  Viruses 20100501

• Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.

  AIDS (London, England) 20100424

• Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.

  Paediatric drugs 20100401

• Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.

  Journal watch. AIDS clinical care 20100401

• Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line.

  The new microbiologica 20100401

• Formation of transient dimers by a retroviral protease.

  The Biochemical journal 20100329

• Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.

  AIDS (London, England) 20100327

• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

  The Journal of infectious diseases 20100315

• Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation.

  Journal of molecular modeling 20100301

• Trends in uptake of recently approved antiretrovirals within a national healthcare system.

  HIV medicine 20100301

• HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

  International journal of STD & AIDS 20100301

• Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100301

• Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

  Xenobiotica; the fate of foreign compounds in biological systems 20100301

• HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.

  AIDS research and human retroviruses 20100301

• [Current topics on drug-resistant HIV in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20100301

• Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.

  AIDS research and human retroviruses 20100301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100301

• FDA notifications. Labeling changed on Prezista.

  AIDS alert 20100301

• Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.

  Bioorganic & medicinal chemistry letters 20100201

• Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.

  International journal of STD & AIDS 20100201

• Current drugs in clinical study.

  Project Inform perspective 20100201

• HIV Genetic Diversity and Drug Resistance.

  Viruses 20100201

• HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

  Journal of medicinal chemistry 20100128

• The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

  AIDS (London, England) 20100116

• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  Antiviral research 20100101

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.

  AIDS research and human retroviruses 20100101

• Towards a Patent Pool for HIV Medicines: The Background.

  The open AIDS journal 20100101

• Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

  The open AIDS journal 20100101

• Pooling ARV Drug Patents: A Pro-Access Fitting Strategy?

  The open AIDS journal 20100101

• Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.

  Antiviral therapy 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.

  Intervirology 20100101

• Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.

  The open AIDS journal 20100101

• [Approach to establishing and evaluating clinical relevance of drug interactions in HIV patients: 2009 update].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

  Antiviral therapy 20100101

• Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.

  Antiviral therapy 20100101

• Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.

  Antiviral therapy 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

  European journal of medical research 20100101

• Forecasting drug utilization and expenditure in a metropolitan health region.

  BMC health services research 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• Dynamics of lamin-A processing following precursor accumulation.

  PloS one 20100101

• An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.

  PloS one 20100101

• Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?

  European journal of medical research 20100101

• Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

  Antiviral therapy 20100101

• The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.

  Drug metabolism and pharmacokinetics 20100101

• Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

  PloS one 20100101

• Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells.

  AIDS research and therapy 20100101

• High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.

  Biological & pharmaceutical bulletin 20100101

• Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.

  European journal of medical research 20100101

• Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

  Antiviral therapy 20100101

• Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.

  HIV clinical trials 20100101

• Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.

  HIV clinical trials 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

  AIDS reviews 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir.

  Drug metabolism and pharmacokinetics 20100101

• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

  Retrovirology 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

  HIV clinical trials 20100101

• Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

  Antiviral therapy 20100101

• The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation.

  PloS one 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.

  AIDS research and therapy 20100101

• Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

  PloS one 20100101

• Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors.

  PloS one 20100101

• A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

  PharmacoEconomics 20100101

• Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

  PharmacoEconomics 20100101

• Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

  PharmacoEconomics 20100101

• US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

  PharmacoEconomics 20100101

• Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

  PharmacoEconomics 20100101

• Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.

  PharmacoEconomics 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

  Infection and drug resistance 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• New and improved strategies for the treatment of gout.

  International journal of nephrology and renovascular disease 20100101

• Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20091210

• Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091208

• Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus.

  Clinical and experimental dermatology 20091201

• Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

  Protein science : a publication of the Protein Society 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• [Safety and tolerability of etravirine].

  Enfermedades infecciosas y microbiologia clinica 20091201

• Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease.

  Interdisciplinary sciences, computational life sciences 20091201

• HIV-1 Protease: Structural Perspectives on Drug Resistance.

  Viruses 20091201

• Current and Novel Inhibitors of HIV Protease.

  Viruses 20091201

• How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

  AIDS (London, England) 20091113

• Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

  AIDS (London, England) 20091113

• [Status of anti-HIV drug development and an overview of combined chemotherapy].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20091110

• Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

  HIV medicine 20091101

• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).

  Current opinion in HIV and AIDS 20091101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

  Talanta 20091015

• Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.

  HIV medicine 20091001

• New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

  Expert opinion on pharmacotherapy 20091001

• A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• The Place of protease inhibitors in antiretroviral treatment.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20091001

• Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

  AIDS (London, England) 20090924

• Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

  AIDS (London, England) 20090910

• Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient.

  AIDS (London, England) 20090910

• New developments in HIV drug resistance.

  The Journal of antimicrobial chemotherapy 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

  Biological & pharmaceutical bulletin 20090901

• Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.

  British journal of clinical pharmacology 20090901

• [Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

  AIDS (London, England) 20090824

• Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090801

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.

  AIDS (London, England) 20090731

• Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20090709

• Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090701

• Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

  Antimicrobial agents and chemotherapy 20090701

• HIV protease inhibitors: recent clinical trials and recommendations on use.

  Expert opinion on pharmacotherapy 20090701

• Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

  British journal of clinical pharmacology 20090701

• Management of paediatric HIV-1 resistance.

  Current opinion in infectious diseases 20090601

• Etravirine: new drug. Multidrug-resistant HIV: another option.

  Prescrire international 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

  HIV medicine 20090501

• Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.

  Journal of managed care pharmacy : JMCP 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

  Journal of medicinal chemistry 20090423

• 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

  Journal of medicinal chemistry 20090423

• A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090415

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

  AIDS research and human retroviruses 20090401

• Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

  Clinical therapeutics 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

  AIDS (London, England) 20090327

• Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.

  Proteins 20090301

• GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

  Antimicrobial agents and chemotherapy 20090301

• Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

  The Journal of antimicrobial chemotherapy 20090301

• Transplacental passage of ritonavir-boosted darunavir in two pregnant women.

  International journal of STD & AIDS 20090301

• Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.

  PLoS computational biology 20090301

• The fusion inhibitor enfuvirtide in recent antiretroviral strategies.

  Current opinion in HIV and AIDS 20090301

• Prezista fares better than Kaletra in first line therapy.

  Project Inform perspective 20090301

• Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.

  Journal of acquired immune deficiency syndromes (1999) 20090201

• Pharmacologic aspects of new antiretroviral drugs.

  Current HIV/AIDS reports 20090201

• Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?

  Journal of acquired immune deficiency syndromes (1999) 20090201

• FDA notifications. FDA OKs new pediatric dosing for darunavir.

  AIDS alert 20090201

• Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

  AIDS (London, England) 20090128

• The use of darunavir/ritonavir as intensification in low viremic HIV-infected patients treated with boosted protease inhibitor-containing regimens.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.

  AIDS clinical care 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

  PloS one 20090101

• Darunavir: a review of its use in the management of HIV infection in adults.

  Drugs 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Drug interactions with new and investigational antiretrovirals.

  Clinical pharmacokinetics 20090101

• Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.

  Therapeutics and clinical risk management 20090101

• Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

  Journal of the International AIDS Society 20090101

• Hypersensitivity reaction to darunavir and desensitization protocol.

  Journal of investigational allergology & clinical immunology 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.

  HIV clinical trials 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

  Antiviral therapy 20090101

• First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better.

  AIDS reviews 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• [Desensitization to tipranavir caused by toxicodermia].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

  Core evidence 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

  Journal of acquired immune deficiency syndromes (1999) 20081215

• Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.

  Journal of molecular biology 20081205

• Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.

  Antimicrobial agents and chemotherapy 20081201

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• [Rational use of modern substances for the treatment of HIV-infection].

  Der Internist 20081201

• Use of darunavir and enfuvirtide in a pregnant woman.

  International journal of STD & AIDS 20081201

• [Pharmacological and clinical profile of Darnavir (Prezista)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20081201

• FDA approves darunavir.

  AIDS patient care and STDs 20081201

• FDA notifications. Darunavir label has these changes.

  AIDS alert 20081201

• US FDA expands approval for Johnson & Johnson HIV drug.

  The AIDS reader 20081201

• Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.

  AIDS clinical care 20081201

• Darunavir now approved for use in treatment-naive patients.

  AIDS clinical care 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.

  AIDS (London, England) 20081112

• Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

  The Journal of antimicrobial chemotherapy 20081101

• Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

  The Journal of antimicrobial chemotherapy 20081101

• Pharmacologic aspects of new antiretroviral drugs.

  Current infectious disease reports 20081101

• Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.

  AIDS patient care and STDs 20081101

• Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?

  Current opinion in HIV and AIDS 20081101

• Approaches to the design of HIV protease inhibitors with improved resistance profiles.

  Current opinion in HIV and AIDS 20081101

• [Role of the new molecules in antiretroviral therapy. Position of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.

  Journal of medicinal chemistry 20081023

• Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20081009

• Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

  AIDS research and human retroviruses 20081001

• [Introduction. Darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Chemical characteristics, mechanism of action and antiviral activity of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in treatment-naïve patients. The ARTEMIS study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir as first-line therapy. The TITAN study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Safety and tolerability of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in HIV/HVC/HVB coinfection].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Pharmacological interactions with darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Resistance to darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Position of darunavir in antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• HIV-protease inhibitors block the enzymatic activity of purified Ste24p.

  Biochemical and biophysical research communications 20080919

• Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

  AIDS (London, England) 20080912

• New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.

  Sexual health 20080901

• Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.

  The AIDS reader 20080901

• A frontal mucocele caused by an immune reconstitution inflammatory syndrome in a patient with HIV infection.

  Rhinology 20080901

• HIV infection in the elderly.

  Clinical interventions in aging 20080901

• Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

  Journal of medicinal chemistry 20080814

• Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.

  British journal of clinical pharmacology 20080801

• Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.

  Journal of medical virology 20080801

• Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

  Journal of molecular biology 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

  Prescrire international 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

  AIDS (London, England) 20080731

• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  The New England journal of medicine 20080724

• Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

  The Journal of infection 20080701

• Induction effects of ritonavir: implications for drug interactions.

  The Annals of pharmacotherapy 20080701

• Health Canada links darunavir to serious liver adverse effects.

  The AIDS reader 20080701

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Darunavir: after multiple antiretroviral treatment failure: another option.

  Prescrire international 20080601

• New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.

  Journal of HIV therapy 20080601

• Evaluating the potency of HIV-1 protease drugs to combat resistance.

  Proteins 20080515

• Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.

  Journal of the American Chemical Society 20080514

• Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.

  The Journal of biological chemistry 20080509

• Dog model with implanted pump to test boosters for antiretroviral medication.

  International journal of pharmaceutics 20080501

• Development of an implantable infusion pump for sustained anti-HIV drug administration.

  International journal of pharmaceutics 20080501

• Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.

  Journal of medical virology 20080501

• FDA alerts doctors to Prezista's possible link to liver damage, deaths.

  The AIDS reader 20080501

• Inhibitory quotient in HIV pharmacology.

  Current opinion in HIV and AIDS 20080501

• [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].

  MMW Fortschritte der Medizin 20080428

• [HIV therapy and adherence].

  MMW Fortschritte der Medizin 20080428

• A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.

  The Journal of biological chemistry 20080411

• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

  Antimicrobial agents and chemotherapy 20080401

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• Liver toxicity warning for darunavir.

  AIDS patient care and STDs 20080401

• New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists.

  Therapeutics and clinical risk management 20080401

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• FDA notifications. New 600 mg tablet strength for darunavir is approved by FDA.

  AIDS alert 20080401

• FDA notifications. Tibotec issues Dear Health Care Professional letter.

  AIDS alert 20080401

• Efficient synthesis of (3R,3aS,6aR)- hexahydrofuro[2,3-b]furan-3-ol from glycolaldehyde.

  Organic letters 20080320

• Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.

  AIDS (London, England) 20080312

• Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center.

  Current medical research and opinion 20080301

• Resistance profile of darunavir: combined 24-week results from the POWER trials.

  AIDS research and human retroviruses 20080301

• [New drugs for HIV infection].

  Revue de l'infirmiere 20080301

• Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.

  AIDS (London, England) 20080130

• [New therapeutic options in protracted HIV-infected patients with virological failure].

  Medicina clinica 20080126

• Response to 'key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients'.

  AIDS (London, England) 20080102

• Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

  Accounts of chemical research 20080101

• HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.

  Trends in pharmacological sciences 20080101

• Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.

  Journal of clinical pharmacology 20080101

• Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.

  Journal of chemical information and modeling 20080101

• Drug interactions between HIV protease inhibitors and acid-reducing agents.

  Clinical pharmacokinetics 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

  AIDS reviews 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Darunavir: pharmacokinetics and drug interactions.

  Antiviral therapy 20080101

• Warning on hepatotoxicity of darunavir.

  AIDS reviews 20080101

• Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.

  HIV clinical trials 20080101

• Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

  Antiviral therapy 20080101

• Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

  Clinical drug investigation 20080101

• Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.

  Antiviral therapy 20080101

• Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

  AIDS reviews 20080101

• Emerging resistance profiles of newly approved antiretroviral drugs.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.

  Antiviral therapy 20080101

• Impending flop for brand antiretrovirals in the emerging markets?

  The open AIDS journal 20080101

• Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

  HIV clinical trials 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

  Bioorganic & medicinal chemistry 20071215

• Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20071201

• Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.

  The Journal of antimicrobial chemotherapy 20071201

• Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.

  Therapeutic drug monitoring 20071201

• HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• Relative antiviral efficacy should not be inferred from cross-trial comparisons.

  HIV medicine 20071101

• Randomized trials to optimize treatment of multidrug-resistant tuberculosis.

  PLoS medicine 20071101

• Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis).

  Journal of acquired immune deficiency syndromes (1999) 20071101

• How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.

  European journal of medical research 20071015

• Defining HIV susceptibility to new antiretroviral agents--darunavir.

  The Journal of infectious diseases 20071015

• Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.

  The Journal of infectious diseases 20071015

• Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

  The Journal of antimicrobial chemotherapy 20071001

• Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071001

• The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.

  Biological & pharmaceutical bulletin 20071001

• Darunavir.

  Drugs of today (Barcelona, Spain : 1998) 20071001

• Darunavir phase 3 study data released.

  AIDS patient care and STDs 20071001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Tipranavir: a new option for the treatment of drug-resistant HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915

• Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

  Journal of medicinal chemistry 20070906

• In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

  Antimicrobial agents and chemotherapy 20070901

• Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

  Journal of acquired immune deficiency syndromes (1999) 20070901

• Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070901

• Predicting HIV care costs using CD4 counts from clinical trials.

  The American journal of managed care 20070901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070901

• [Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20070901

• Development of therapeutics for AIDS: structure-based molecular targeting.

  Tuberculosis (Edinburgh, Scotland) 20070801

• Darunavir: a second-generation protease inhibitor.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070801

• Darunavir (TMC114): a new HIV-1 protease inhibitor.

  Expert opinion on pharmacotherapy 20070801

• Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.

  AIDS patient care and STDs 20070801

• Darunavir: a nonpeptidic antiretroviral protease inhibitor.

  Clinical therapeutics 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

  AIDS (London, England) 20070711

• No patient left behind--better treatments for resistant HIV infection.

  Lancet (London, England) 20070707

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20070707

• Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

  Lancet (London, England) 20070707

• A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20070601

• Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.

  AIDS (London, England) 20070531

• Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.

  HIV medicine 20070501

• Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.

  HIV medicine 20070501

• HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

  PLoS computational biology 20070501

• Tibotec and Aspen collaborate on Prezista.

  AIDS patient care and STDs 20070501

• Darunavir: promising initial results.

  Lancet (London, England) 20070407

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

  Lancet (London, England) 20070407

• Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.

  Proteins 20070401

• The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

  Journal of clinical pharmacology 20070401

• When and how to use tipranavir and darunavir.

  The AIDS reader 20070401

• Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.

  European journal of medical research 20070326

• Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.

  The AIDS reader 20070301

• Editorial comment: impact of darunavir for salvage therapy.

  The AIDS reader 20070301

• Prezista gets EU approval.

  AIDS patient care and STDs 20070301

• Resistance to newly approved and investigational protease inhibitors.

  Current opinion in HIV and AIDS 20070301

• Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

  AIDS (London, England) 20070219

• Darunavir (TMC114) approved by the FDA.

  AIDS alert 20070201

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• Anti-HIV agents. Darunavir and some antidepressants.

  TreatmentUpdate 20070101

• Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.

  HIV clinician 20070101

• Key reports from the XV International HIV Drug Resistance Workshop 2006.

  Antiviral therapy 20070101

• 48-week study results show DRV's staying power.

  IAPAC monthly 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

  Scandinavian journal of infectious diseases 20070101

• Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.

  Drugs in R&D 20070101

• Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients.

  HIV clinical trials 20070101

• Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.

  Antiviral therapy 20070101

• Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.

  Antiviral therapy 20070101

• Clinical pharmacokinetics of darunavir.

  Clinical pharmacokinetics 20070101

• Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.

  HIV clinical trials 20070101

• Anti-HIV agents. Darunavir shows its strength.

  TreatmentUpdate 20070101

• Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.

  HIV clinical trials 20070101

• Darunavir: in the treatment of HIV-1 infection.

  Drugs 20070101

• Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy.

  Drugs 20070101

• Darunavir in the treatment of HIV-1 infection: a viewpoint by Renslow Sherer.

  Drugs 20070101

• Enantioselective synthesis and selective monofunctionalization of (4R,6R)-4,6- dihydroxy-2,8-dioxabicyclo[3.3.0]octane.

  Organic letters 20061207

• Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.

  Current medical research and opinion 20061201

• British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

  HIV medicine 20061101

• XVI International AIDS Conference: Part 2.

  The AIDS reader 20061101

• Clinical trials for heavily pretreated patients: update in 2006.

  Current opinion in HIV and AIDS 20061101

• Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

  Journal of molecular biology 20061013

• TMC114 approved for resistant patients.

  AIDS patient care and STDs 20061001

• The latest in antiretroviral therapy.

  Drug news & perspectives 20061001

• Darunavir (Prezista) for HIV infection.

  The Medical letter on drugs and therapeutics 20060911

• Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.

  ChemMedChem 20060901

• Management of the highly experienced patient.

  Current opinion in HIV and AIDS 20060901

• Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20060824

• FDA approval: darunavir.

  AIDS clinical care 20060801

• FDA clears HIV drug for patients with resistant virus.

  The AIDS reader 20060801

• Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20060713

• Tribulations and trials in HIV disease, Part 2.

  The AIDS reader 20060601

• The clinical pharmacology of antiretrovirals in development.

  Expert opinion on drug metabolism & toxicology 20060601

• FDA approves new PI.

  IAPAC monthly 20060601

• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  Bioorganic & medicinal chemistry letters 20060401

• Report from the 13th retrovirus conference. New data on TMC114 and TMC125.

  AIDS clinical care 20060401

• Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

  Journal of medicinal chemistry 20060223

• Prezista (darunavir, TMC-114) approved; may be important treatment advance.

  AIDS treatment news 20060101

• Etravirine: R165335, TMC 125, TMC-125, TMC125.

  Drugs in R&D 20060101

• New drugs: ranibizumab, posaconazole, and darunavir.

  Journal of the American Pharmacists Association : JAPhA 20060101

• Anti-HIV agents. Darunavir shows its strength.

  TreatmentUpdate 20060101

• Drug interactions. Interactions with TMC114 and TMC125.

  TreatmentUpdate 20060101

• New HIV treatment.

  FDA consumer 20060101

• Stereoselective and efficient synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.

  Organic letters 20051222

• [Protease inhibitors].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20051201

• Protease inhibitors: the current status.

  Journal of HIV therapy 20051201

• Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

  The FEBS journal 20051001

• HIV Pathogenesis and Treatment - Third International AIDS Society Conference.

  IDrugs : the investigational drugs journal 20051001

• Meeting notes from the 3rd IAS Conference. New drugs.

  AIDS clinical care 20051001

• New drugs.

  HIV medicine 20050701

• TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.

  AIDS (London, England) 20050610

• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

  Antimicrobial agents and chemotherapy 20050601

• Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20050519

• New PI may offer hope to triple class patients.

  AIDS patient care and STDs 20050501

• [New drugs--hope for salvage patients?].

  MMW Fortschritte der Medizin 20050425

• Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

  Journal of medicinal chemistry 20050324

• Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

  Journal of medicinal chemistry 20050324

• Development of a capillary electrophoretic method for the separation of diastereoisomers of a new human immunodeficiency virus protease inhibitor.

  Electrophoresis 20050201

• New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.

  Positively aware : the monthly journal of the Test Positive Aware Network 20050101

• A lame duck, a dark horse, and a goat.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20050101

• Anti-HIV agents. TMC114--an overview.

  TreatmentUpdate 20050101

• Anti-HIV agents. Interactions with TMC114.

  TreatmentUpdate 20050101

• Anti-HIV agents. What the future holds for TMC114.

  TreatmentUpdate 20050101

• Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114).

  The Journal of organic chemistry 20041112

• TMC-114 (Tibotec).

  Current opinion in investigational drugs (London, England : 2000) 20040801

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040501

• High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

  Journal of molecular biology 20040423

• Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.

  AIDS reviews 20040101

• Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20031001

• Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

  Bioorganic & medicinal chemistry letters 19980317